MX2009001745A - Tratamiento de enfermedades oculares. - Google Patents

Tratamiento de enfermedades oculares.

Info

Publication number
MX2009001745A
MX2009001745A MX2009001745A MX2009001745A MX2009001745A MX 2009001745 A MX2009001745 A MX 2009001745A MX 2009001745 A MX2009001745 A MX 2009001745A MX 2009001745 A MX2009001745 A MX 2009001745A MX 2009001745 A MX2009001745 A MX 2009001745A
Authority
MX
Mexico
Prior art keywords
neovascularisation
treatment
ocular diseases
protease
group
Prior art date
Application number
MX2009001745A
Other languages
English (en)
Inventor
Ahmed Aftab
Lucia Desser
Bernhard Lotz
Thomas Mohr
Original Assignee
Marlyn Nutraceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marlyn Nutraceuticals Inc filed Critical Marlyn Nutraceuticals Inc
Publication of MX2009001745A publication Critical patent/MX2009001745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con el uso de al menos una proteasa para la elaboración de un medicamento para el tratamiento y/o prevención de enfermedades oculares relacionadas con neo-angiogénesis, seleccionadas del grupo que consiste de degeneración macular relacionada con la edad (AMD), neo-vascularización coroidea, enfermedad de Hippel-Lindau, neo-vascularización del iris, retinopatía proliferativa isquémica, neo-vascularización de la cornea, retinopatía proliferativa de drepanocitos, en donde se selecciona al menos una proteasa del grupo que consiste de: proteasas vegetales, de animales no mamíferos y microbianas.
MX2009001745A 2006-08-16 2007-08-16 Tratamiento de enfermedades oculares. MX2009001745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0137606A AT504159A1 (de) 2006-08-16 2006-08-16 Verwendung von proteasen
PCT/AT2007/000393 WO2008019417A2 (en) 2006-08-16 2007-08-16 Treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MX2009001745A true MX2009001745A (es) 2009-07-10

Family

ID=38677891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001745A MX2009001745A (es) 2006-08-16 2007-08-16 Tratamiento de enfermedades oculares.

Country Status (15)

Country Link
US (1) US9795656B2 (es)
EP (1) EP2056863B1 (es)
JP (1) JP2010500382A (es)
CN (1) CN101505790A (es)
AT (1) AT504159A1 (es)
CA (1) CA2658564A1 (es)
DK (1) DK2056863T3 (es)
ES (1) ES2628813T3 (es)
HU (1) HUE034862T2 (es)
MX (1) MX2009001745A (es)
PL (1) PL2056863T3 (es)
PT (1) PT2056863T (es)
RU (1) RU2472523C2 (es)
SI (1) SI2056863T1 (es)
WO (1) WO2008019417A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009290466B2 (en) * 2008-09-10 2014-06-12 Pt. Dexa Medica Composition of thrombolytic agent and anti thrombosis and also its production method
EP3037102A1 (en) * 2009-11-23 2016-06-29 Stephen F. Olmstead Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
CA2835664C (en) 2011-05-12 2019-02-05 Smith & Nephew Orthopaedics Ag Wound debridement compositions containing seaprose and methods of wound treatment using same
CA2872530A1 (en) 2012-05-11 2013-11-14 Smith & Nephew, Inc. Use of seaprose to remove bacterial biofilm
ITMI20121997A1 (it) * 2012-11-23 2014-05-24 Velleja Res Srl Composizioni fibrinolitiche per la prevenzione e il trattamento degli stati flebotrombotici
ITMI20130117A1 (it) * 2013-01-25 2014-07-26 Gnosis Spa Composizioni comprendenti condroitin solfato, enzimi proteolitici e composti sulfidrilati capaci di migliorare la biodisponibilita' del condroitin solfato
US20140212405A1 (en) 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
CA3025011A1 (en) 2016-05-27 2017-11-30 Nattocat, LLC Compositions and methods for thromboembolism dissolution
EP3490588A1 (en) 2016-07-27 2019-06-05 Smith&Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
JP7429503B2 (ja) * 2019-06-24 2024-02-08 小林製薬株式会社 ナットウキナーゼを含む経口組成物
TW202202168A (zh) * 2020-07-07 2022-01-16 洪啟庭 用於改善玻璃體混濁的組成物及其應用
CN113769073A (zh) * 2021-10-15 2021-12-10 杭州鑫伟低碳技术研发有限公司 一种利用生物酶治疗眼底出血的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030612A (en) * 1994-11-22 2000-02-29 Phairson Medical Inc. Antimicrobial uses of multifunctional enzyme
SK59999A3 (en) * 1996-11-19 2000-01-18 Searle & Co Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
DE19726251C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme zur Behandlung von Uveitis
KR20010052371A (ko) * 1998-05-22 2001-06-25 엔트리메드 인코포레이티드 세린 프로테아제를 이용한 내피 세포 증식 억제 및안기오게네시스 조절을 위한 조성물 및 방법
WO2000001410A1 (en) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
US20040086537A1 (en) * 1998-08-20 2004-05-06 Jun Inoue Prophylactic or threapeutic composition for ocular circulation disorders
US20030027998A1 (en) 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7559718B2 (en) * 1999-01-27 2009-07-14 Trimble Navigation Limited Transducer arrangement
EP1377312A4 (en) * 2001-03-22 2004-10-06 Andel Inst Van ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
US7381404B2 (en) * 2002-07-02 2008-06-03 The Regents Of The University Of California Treatment for dry macular degeneration
CA2529589A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
US7354569B2 (en) * 2003-07-11 2008-04-08 Colgate-Palmolive Company Chewable antiplaque confectionery dental composition
JPWO2005056784A1 (ja) * 2003-12-15 2007-07-05 独立行政法人科学技術振興機構 インスリン誘導性ポリペプチド
ES2640284T3 (es) * 2004-04-12 2017-11-02 Catalyst Biosciences, Inc. Polipéptidos MT-SP1 mutantes
EP1735438A2 (en) * 2004-04-12 2006-12-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
JPWO2006025276A1 (ja) * 2004-08-31 2008-05-08 国立大学法人 熊本大学 ナットウキナーゼを含む眼科疾患の治療・予防剤
JP2009535371A (ja) * 2006-05-04 2009-10-01 フォベア、ファルマスティカル、ソシエテ、アノニム 血管新生性疾患の治療のための方法

Also Published As

Publication number Publication date
EP2056863B1 (en) 2017-03-22
PT2056863T (pt) 2017-07-04
CN101505790A (zh) 2009-08-12
US9795656B2 (en) 2017-10-24
RU2009109358A (ru) 2010-09-27
JP2010500382A (ja) 2010-01-07
WO2008019417A3 (en) 2008-05-29
AT504159A1 (de) 2008-03-15
US20110311509A1 (en) 2011-12-22
ES2628813T3 (es) 2017-08-04
SI2056863T1 (sl) 2017-10-30
DK2056863T3 (en) 2017-07-10
HUE034862T2 (en) 2018-03-28
CA2658564A1 (en) 2008-02-21
RU2472523C2 (ru) 2013-01-20
EP2056863A2 (en) 2009-05-13
PL2056863T3 (pl) 2017-11-30
WO2008019417A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
MX2009001745A (es) Tratamiento de enfermedades oculares.
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
WO2008140052A1 (ja) ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
Arance-Gil et al. Corneal cross-linking for Acanthamoeba keratitis in an orthokeratology patient after swimming in contaminated water
BR112014008759A2 (pt) tratamento de doença ocular
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
MX2010003774A (es) Formulaciones oftalmicas acuosas.
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
Holland et al. Antibiotic resistance in acute postoperative endophthalmitis
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
MX2007008848A (es) Metodos y composiciones para el tratamiento de desordenes oculares.
DK1904056T3 (da) Anvendelse af et macrolid til at gendanne korneal fölelse
WO2007035473A3 (en) Pharmaceutical delivery device and method for providing ocular treatment
TW200626721A (en) RNAi inhibition of CTGF for treatment of ocular disorders
BRPI0608152A2 (pt) formulações para tratamento ocular
WO2010093945A3 (en) Uveoscleral drug delivery implant and methods for implanting the same
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2008111497A1 (ja) トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
WO2006039252A3 (en) Compositions and methods for treating ophthalmic diseases
WO2007075720A3 (en) Topical mecamylamine formulations for ocular administration and uses thereof
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
DE502005008759D1 (de) In vitro aus knochenmarkstammzellen differenzierteerwendung
WO2007089673A8 (en) Compositions and methods for treatment of ophthalmic diseases and disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal